SESTRI LEVANTE, LIGURIA — An 18-year-old woman is dead, prompting many young people in her area to cancel their previous plans for injections.
Ms. Camilla Canepa received the first dose of experimental AstraZeneca viral vector DNA on May 25, according to several Italian media sources. It was an “open day” for anyone over the age of 18 to receive experimental injections, particularly AstraZeneca.
She checked into the emergency room at Lavagna Hospital on June 3, complaining of severe headaches and extreme light sensitivity. A CT scan and neurological tests found nothing, so doctors discharged her with an order to return in 15 days for further tests. But Ms. Canepa returned to the ER at San Martino Hospital in Genoa just two days later. She now suffered from paralysis in at least one part of her body.
Ms. Canepa was diagnosed with cavernous sinus thrombosis, meaning a blood clot in the space between the eye sockets and brain. It blocked the primary vein between the head and heart. Doctors also discovered that she was bleeding inside her brain. Ms. Canepa underwent two surgeries, one to remove the blood clot and the second to relieve pressure in her head caused by the bleeding. But the damage was too great to overcome.
Ms. Canepa passed away on June 10.
More on this story: Italy Suspends AstraZeneca’s COVID Vaccine After Teen’s Brain Hemorrhage Death